Key result
Lercanidipine plus carvedilol is linked to improved EF and LV remodeling versus carvedilol alone.
Why the study?
The study was conducted to evaluate the effect of combining lercanidipine and carvedilol on the functional state of the heart in patients with arterial hypertension and chronic heart failure.
Does the combination of lercanidipine and carvedilol improve echocardiographic parameters of systolic and diastolic function compared to carvedilol alone in patients with chronic heart failure and arterial hypertension?
Cohort (n=68)
No
Does the combination of lercanidipine and carvedilol improve echocardiographic parameters of systolic and diastolic function compared to carvedilol alone in patients with chronic heart failure and arterial hypertension?
p-value: p=<0.05
The addition of lercanidipine to carvedilol significantly improves both systolic and diastolic echocardiographic parameters in patients with hypertension and mild-to-moderate heart failure compared to carvedilol monotherapy.
To study the effect of a combination of lercanidipine and carvedilol on heart failure, 36 patients with arterial hypertension and I–III functional state heart failure according to the New York Heart Association classification were enrolled in the study (Group A). The control group consisted of 32 patients with the same pathology (Group B). The groups were divided into subgroups (3 per group) according to the functional states I, II, and III. Subgroups from Group A received lercanidipine and carvedilol, while subgroups from Group B received only carvedilol for 6 months. After treatment, significant improvements in systolic and diastolic function parameters were observed in all subgroups from Group A (p<0.05). The magnitude of improvement was most significant in patients with functional class I and progressively attenuated in functional classes II and III. In all subgroups of Group B, only early diastolic filling deceleration time and left ventricular isovolumetric relaxation time improved reliably (p<0.05).
No takes yet. Share an insight, caveat, or question.
Imamaliev et al. (2025) conducted a cohort in Chronic heart failure and arterial hypertension (n=68). Lercanidipine and carvedilol vs. Carvedilol 12.5–25 mg once daily was evaluated on Improvement in systolic and diastolic function parameters (EF, LVEDV, LVMMI, E, A, E/A, IVRT, DT) (p=<0.05). The combination of lercanidipine and carvedilol significantly improved systolic and diastolic function parameters, including ejection fraction and left ventricular remodeling, compared to carvedilol alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: